Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics, Inc. shareholder Wellington Management Group LLP and affiliated entities report beneficial ownership of 8,079,608 shares of common stock, representing 12.16% of the class. The shares are held of record by clients of various Wellington investment advisers, including Vanguard Health Care Fund.
The Wellington entities report no sole voting or dispositive power and instead share voting and/or dispositive power over these shares through their advisory relationships. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Celldex.
State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Celldex Therapeutics, Inc. common stock. As of 12/31/2025, State Street reported beneficial ownership of 3,397,713 shares, representing 5.1% of Celldex’s outstanding common stock.
State Street reported shared voting power over 3,194,178 shares and shared dispositive power over 3,397,713 shares, with no sole voting or dispositive authority. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Celldex.
Celldex Therapeutics senior executive reports stock option exercises. A company officer serving as Senior Vice President and Chief Business Officer filed a Form 4 covering two option exercises in Celldex Therapeutics, Inc. common stock on 12/15/2025. The reporting person acquired 8,333 shares at an exercise price of $9.0165 per share and 11,000 shares at an exercise price of $2.78 per share through the exercise of incentive stock options.
Following these transactions, the officer beneficially owns 20,097 shares of Celldex common stock directly, which includes 764 shares acquired under the company’s 2004 Employee Stock Purchase Plan. After the exercises, one option grant for 8,333 shares expiring on 06/13/2028 remains partially outstanding with 5,000 derivative securities beneficially owned, while a second option grant for 11,000 shares expiring on 06/19/2029 has been fully exercised.
Celldex Therapeutics officer Freddy A. Jimenez reported selling 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025 at $29.095 per share. Following this sale, he directly owns 30,796 shares. The report identifies him as the company’s Senior Vice President and General Counsel and indicates the Form 4 was filed for a single reporting person.
Celldex Therapeutics (CLDX) filed a Form 4 reporting option exercises and a share sale by an insider. On 11/13/2025, the reporting person exercised three incentive stock options for 6,876 shares at $9.0165, 26,672 shares at $10.38, and 15,750 shares at $22.48, receiving common stock in each case. On the same date, they sold 49,298 common shares at a weighted average price of $24.0005 per share, with trades executed between $24.00 and $24.05. After these transactions, the insider directly owned 20,833 common shares and held 7,875 derivative securities (options) directly.
Celldex Therapeutics (CLDX) reported a Form 4 for its SVP & Chief Commercial Officer, noting the grant of 100,000 stock options on 11/10/2025 under the company’s 2021 Omnibus Equity Incentive Plan at an exercise price of $22.67 per share. The options expire on 11/10/2035.
The filing states 25% of the award vests on 11/10/2026, with the remainder vesting in equal quarterly installments over the next 12 quarters. Following the grant, 100,000 derivative securities are listed as beneficially owned in direct form.
Celldex Therapeutics (CLDX) filed a Form 3, the initial statement of beneficial ownership for a company insider. The reporting person is Teri Lawver, who serves as SVP & Chief Commercial Officer. The filing states that no securities are beneficially owned by the reporting person.
The date of event is 11/10/2025, and the form was filed on an individual basis. The document was signed by /s/ Sam Martin, attorney-in-fact for Teri Lawver on 11/12/2025.
Celldex Therapeutics (CLDX) filed its Q3 2025 10-Q, reporting no revenue for the quarter and higher operating spend as clinical programs advanced. For the three months ended September 30, 2025, operating expenses were $73.6 million and the company recorded a net loss of $67.0 million (vs. $42.1 million a year ago). For the nine months, operating expenses were $201.6 million with a net loss of $177.4 million.
Liquidity remains strong: as of September 30, 2025, cash, cash equivalents and marketable securities totaled $583.2 million. Net cash used in operating activities was $147.0 million for the nine months. Management states these resources are expected to fund operations for at least the next twelve months from issuance. R&D spend is led by the barzolvolimab (anti‑KIT) program, which accounted for $133.97 million of R&D in the nine-month period; CDX‑622 and other programs accounted for the balance. An at‑the‑market facility with $300.0 million registered capacity remained unsold at quarter end. Common shares outstanding were 66,446,846 at September 30, 2025.
Celldex Therapeutics (CLDX) reported that it furnished a press release announcing its third‑quarter 2025 financial results. The company disclosed this under Item 2.02 and attached the full press release as Exhibit 99.1, which is incorporated by reference.
The company stated the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as expressly set forth by specific reference.
Celldex Therapeutics filed a Form 8-K to report that, on August 19, 2025, it issued a press release with results from its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The company attached this press release as Exhibit 99.1 and incorporated it by reference, making the clinical trial outcome an official part of its public disclosures.